Two Sigma Advisers’s Utah Medical Products UTMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,900
| Closed | -$274K | – | 2064 |
|
|
2025
Q4 | $274K | Sell |
4,900
-2,300
| -32% | -$133K | ﹤0.01% | 2010 |
|
|
2025
Q3 | $453K | Sell |
7,200
-8,600
| -54% | -$509K | ﹤0.01% | 1799 |
|
|
2025
Q2 | $899K | Sell |
15,800
-7,300
| -32% | -$397K | ﹤0.01% | 1496 |
|
|
2025
Q1 | $1.29M | Buy |
23,100
+3,100
| +16% | +$186K | ﹤0.01% | 1347 |
|
|
2024
Q4 | $1.23M | Sell |
20,000
-3,800
| -16% | -$246K | ﹤0.01% | 1366 |
|
|
2024
Q3 | $1.59M | Buy |
23,800
+1,500
| +7% | +$102K | ﹤0.01% | 1191 |
|
|
2024
Q2 | $1.49M | Sell |
22,300
-400
| -2% | -$27.2K | ﹤0.01% | 1358 |
|
|
2024
Q1 | $1.61M | Buy |
22,700
+14,000
| +161% | +$1.05M | ﹤0.01% | 1334 |
|
|
2023
Q4 | $733K | Sell |
8,700
-1,600
| -16% | -$133K | ﹤0.01% | 1771 |
|
|
2023
Q3 | $886K | Buy |
10,300
+5,600
| +119% | +$517K | ﹤0.01% | 1574 |
|
|
2023
Q2 | $438K | Buy |
4,700
+1,000
| +27% | +$94.2K | ﹤0.01% | 1858 |
|
|
2023
Q1 | $351K | Buy |
3,700
+400
| +12% | +$36.8K | ﹤0.01% | 2080 |
|
|
2022
Q4 | $332K | Hold |
3,300
| – | – | ﹤0.01% | 2033 |
|
|
2022
Q3 | $282K | Sell |
3,300
-2,800
| -46% | -$247K | ﹤0.01% | 2065 |
|
|
2022
Q2 | $524K | Sell |
6,100
-2,800
| -31% | -$239K | ﹤0.01% | 1899 |
|
|
2022
Q1 | $800K | Buy |
8,900
+5,300
| +147% | +$487K | ﹤0.01% | 1762 |
|
|
2021
Q4 | $360K | Buy |
+3,600
| New | +$367K | ﹤0.01% | 2079 |
|
|
2020
Q3 | – | Sell |
-2,300
| Closed | -$204K | – | 2637 |
|
|
2020
Q2 | $204K | Hold |
2,300
| – | – | ﹤0.01% | 2243 |
|
|
2020
Q1 | $216K | Hold |
2,300
| – | – | ﹤0.01% | 2144 |
|
|
2019
Q4 | $248K | Sell |
2,300
-300
| -12% | -$30.4K | ﹤0.01% | 2121 |
|
|
2019
Q3 | $249K | Buy |
2,600
+200
| +8% | +$18.6K | ﹤0.01% | 1986 |
|
|
2019
Q2 | $230K | Hold |
2,400
| – | – | ﹤0.01% | 2095 |
|
|
2019
Q1 | $212K | Buy |
+2,400
| New | +$211K | ﹤0.01% | 2099 |
|
|
2018
Q4 | – | Sell |
-2,700
| Closed | -$254K | – | 2468 |
|
|
2018
Q3 | $254K | Hold |
2,700
| – | – | ﹤0.01% | 2008 |
|
|
2018
Q2 | $297K | Buy |
2,700
+600
| +29% | +$62.7K | ﹤0.01% | 2100 |
|
|
2018
Q1 | $208K | Buy |
+2,100
| New | +$187K | ﹤0.01% | 2133 |
|
|
2016
Q3 | – | Sell |
-3,200
| Closed | -$202K | – | 2324 |
|
|
2016
Q2 | $202K | Buy |
+3,200
| New | +$206K | ﹤0.01% | 1856 |
|
Other funds holding UTMD
BIP
VCM
MA
RHJA
Two Sigma Advisers's UTMD Position: Q1 2026 in Review
Two Sigma Advisers sold out of Utah Medical Products (UTMD) in Q1 2026, closing a stake of 4,900 shares — an estimated $274K sold.
Two Sigma Advisers first reported a position in UTMD in Q2 2016 and held it in 27 quarters. The position peaked at $1.61M in Q1 2024. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.
- Two Sigma Advisers reported no remaining Utah Medical Products position as of Q1 2026 after selling out during the quarter.
- Two Sigma Advisers sold 4,900 Utah Medical Products shares in Q1 2026, an estimated $274K.
- Two Sigma Advisers first reported a position in Utah Medical Products in Q2 2016 and held it in 27 quarters.
- Two Sigma Advisers's Utah Medical Products position peaked at $1.61M in Q1 2024.
- 119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.
Based on Two Sigma Advisers's 13F filing for Q1 2026.